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Summary Although cytotoxic chemotherapy is widely used in advanced breast cancer, there are no powerful predictors for the therapy
response. Because topoisomerase Ila (Topo Ila) is the molecular target for the anthracycline class of anti-cancer drugs, we compared the
immunocytochemical assay of Topo Ila with other biomarkers in the prediction of clinical response to Topo II inhibitorchemotherapy. Fifty-five
patients with advanced breast cancer were treated with a single cytotoxic drug, Topo Il-inhibitor, epirubicin (30 mg m-2 weekly up to
1000 mg m-2), as first line cytotoxic chemotherapy. Objective response to treatment was analysed according to UICC criteria. The predictive
value of Topo Ila expression, c-erbB2 oncoprotein, p53 tumour-suppressor protein, oestrogen (ER) and progesterone receptor (PR), S-phase
fraction and DNA ploidy were analysed from representative formalin-fixed paraffin-embedded primary tumour samples. The proportion of
Topo Ila-positive cells (Topo Ila index) failed to predict response to epirubicin therapy. Mean Topo Ila scores in 29 responding patients
were similar when compared with those with no change in disease progression (n = 13) and those with progressive disease (n = 13)
(14.9% ± 11.4% vs 15.5% ± 7.6% vs 17.3% ± 13.2%, not significant). Among the other biomarkers tested, overexpression of c-erbB2
oncoprotein and hormone receptor negativity were significantly associated with poor response. Response rate in patients with c-erbB2-
overexpressing tumours was 32% compared with 65% in patients with no c-erbB2 overexpression (P= 0.0058). Accordingly, the response
rate for ER-positive patients was 67% compared with 26% in ER-negative patients (P = 0.0021). Although both negative ER status and
c-erbB2 overexpression are associated with high Topo Ila expression in breast cancer, step-wise logistic regression analysis showed that ER
and c-erbB2 were associated with therapy response independent of Topo Ila expression. Histological grade, p53, DNA-ploidy, tumour
proliferation rate (S-phase fraction), stage ofthe disease at diagnosis, age of the patient, previous anti-oestrogen therapy or site of metastasis
did not predict the response to epirubicin therapy. In conclusion, despite extensive in vitro evidence, expression of Topo Ila is unlikely to
predict the response to Topo II inhibitor chemotherapy in advanced breast cancer. Among the prognostic biomarkers, overexpression of
c-erbB2 oncogene and negative ER may have predictive value in epirubicin therapy in patients with advanced breast cancer.
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Patients with advanced breast cancer are commonly treated with
cytotoxic chemotherapy. Whereas response to endocrine therapy
can be effectively predicted by hormone receptor status, prediction
of response to cytotoxic chemotherapy currently lacks reliable
predictive markers (Clark, 1996). Such factors would be ofutmost
use, not only in the prediction of response to chemotherapy in
general but also in aiding selection between different types of
cytotoxic chemotherapy. With increasing number of effective
chemotherapeutic agents, selection between different regimens for
individual patients according to the predictive factors might
improve the efficiency ofchemotherapy.
Chemotherapy with anthracyclines (doxorubicin and its deriva-
tives, such as epirubicin) is well established in advanced breast
cancer. The mechanism of action ofthese compounds is related to
the inhibition of topoisomerase II (Topo II) enzyme. Topo II is a
eukaryotic homodimeric enzyme that exists in two isoforms in
human cells: the 170-kDa form (Topo Ila) and the 180-kDa form
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(Topo I1j). Whereas Topo Ila is a key enzyme in DNA metabo-
lism, having key roles in DNA replication and chromosome parti-
tioning during cell division, the function of Topo 111 is poorly
defined (Chen and Liu, 1994; Watt and Hickson, 1994; Froelich-
Ammon and Osheroff, 1995; Wang, 1996). Drugs targeted against
Topo II interfere with its DNA cleavage-rejoining action, trapping
Topo IIa enzyme with DNA in a non-cleavable complex (Chen
and Liu, 1994; Watt and Hickson, 1994; Froelich-Ammon and
Osheroff, 1995). This results in the accumulation of stabilized
double-stranded DNA breaks, which are lethal to the cell at the
G2M-phase of the cell cycle (Froelich-Ammon and Osheroff,
1995; Nitiss and Beck, 1996).
In vitro studies using different experimental designs have
shown that sensitivity to Topo II-inhibiting drugs is dependent on
the expression level ofTopo IIa gene in target cancer cells (Davies
et al, 1988; Fry et al, 1991; Gudkov et al, 1993; Asano et al,
1996a,b; Vassetzky et al, 1996; Withoffet al, 1996a,b). Cells with
a low concentration ofTopo Ilo protein form fewer Topo I-medi-
ated DNA strand breaks and are less sensitive to Topo II-inhibiting
drugs than cells containing a high concentration of Topo llac
(Davies et al, 1988; Fry et al, 1991; Gudkov et al, 1993; Asano et
al, 1996a,b; Vassetzky et al, 1996; Withoffet al, 1996b). These in
vitro findings suggest testing whether assays of Topo IIoc protein
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expression could be used in a clinical setting to predict a patient's
response to Topo II inhibitor chemotherapy. To date, no such clin-
ical studies reporting the relationship between Topo Iloc expression
and chemosensitivity have been published using solid tumours,
although studies on the variability ofTopo 11o expression in breast
tumours have been published (Tuccari et al, 1993; Hellemans et al,
1995; Boege et al, 1996; Jarvinen et al, 1996; Sandri et al, 1996).
In general, high Topo IIc expression is associated with high
cellular proliferation and poor histological differentiation of the
tumour (Tuccari et al, 1994; Hellemans et al, 1995; Boege et al,
1996; Jarvinen et al, 1996; Sandri et al, 1996). In addition, our
recent study on a large number of breast carcinomas indicated
that Topo 11z expression also correlates with negative hormone
receptor content, aneuploidy and c-erbB2 overexpression
(Jarvinen et al, 1996). These all are features that are generally
considered to be related with altered sensitivity to chemothera-
peutic agents.
In the present study, we compared the value of Topo Iloh with
other biomarkers (c-erbB2, p53, ER, PR, S-phase fraction, DNA
ploidy) in the prediction of response to first-line Topo II inhibitor
chemotherapy in 55 patients with advanced breast cancer.
MATERIALS AND METHODS
Patients and tumours
Included in this study were 55 patients with advanced breast
cancer treated with a single-agent chemotherapy programme
comprising Topo II inhibitor, epirubicin (30 mg m-2 weekly up to
1000 mg m-2, for at least 3 months or until the disease progressed)
between 1989 and 1995 in Tampere University Hospital. All
patients received the therapy according to the schedule (no cessa-
tion of therapy due to side-effects). Epirubicin was the first-line
cytotoxic chemotherapy for all patients, but 36 patients had
received hormonal therapy (tamoxifen 20-40 mg day-') before
epirubicin. Primary breast cancers of these patients were diag-
nosed and operated between 1981 and 1994, and the disease-free
interval varied from I to 12.5 years. Twenty-five patients were
primarily node negative (T1-3NOMO), 28 were node positive
(TI-4N1MO), and in two patients the disease was advanced when
diagnosis was made (T3NlM1). All patients were followed up
every 3 weeks by clinical examination and laboratory tests
(haemoglobin, platelets, alanine aminotransferase, alkaline phos-
phatase). Further diagnostic tests (bone scan, chest radiograph,
liver ultrasound and serum tumour marker CA-15-3) were
performed every 3 months to aid in determining the response to
treatment. The response to chemotherapy was classified into four
categories: 'complete response,' CR; 'partial response,' PR; 'no
change in disease progression,' NC; and 'progressive disease,' PD
according to UICC criteria (Hayward et al, 1977). The investiga-
tion was approved by the ethics committee of Tampere University
Hospital and informed consent was obtained from each subject
before enrolment to the study.
Specimen preparation
Routinely formalin-fixed, paraffin-embedded blocks from the
primary tumour lesions were obtained from the institutes in which
the patients were operated. All histopathological diagnoses
were re-evaluated and histopathological grading was performed
according to the Bloom and Richardson system (Bloom and
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Figure 1 The survival of 55 advanced breast cancer patients after initiation
of epirubicin according to the clinical response. Patients with complete or
partial response (CR and PR) have significantly better survival than patients
with no change in disease progression (NC) or progressive disease (PD)
(P < 0.0016, Mantel-Cox test)
Richardson, 1957). Adjacent tissue sections were prepared for
immunohistochemical studies, and 50-,um sections for flow cyto-
metric DNA analysis.
Immunohistochemistry
Immunohistochemistry for Topo Ila was performed using a rabbit
polyclonal Topo Icl antibody (Topo IIo, diluted 1:1000 from
manusfacturer's stock, TopoGEN, Columbus, OH, USA)
(Jarvinen et al, 1996). Tissue sections were cut on adhesive-
treated, poly-L-lysine-coated slides and dried in an oven, 37°C,
overnight and 3 h in an oven at 60°C. Dewaxed sections were
immersed in 10 mm EDTA (pH 8.0) at 80°C and incubated at
120°C (pressure 1.05 bar) for 10 min in an ordinary autoclave for
antigen retrieval (Morgan et al, 1994; Kuukasjarvi et al, 1996).
Slides were washed at room temperature and incubated overnight
at 4°C with the primary antibody. A standard avidin-biotin-perox-
idase complex (ABC) technique (Vectastain Elite, Vector
Laboratories, Burlingame, CA, USA) was used for visualization
with diaminobenzidine as a chromogen. The diaminobenzidine
reaction was intensified with the methenamine silver method as
described elsewhere (Peacock et al, 1991). Sections were counter-
stained with haematoxylin and mounted. Immunostaining was
evaluated light microscopically using an 20x objective, by a
person unaware of clinical data. The Topo IIo index was assessed
by counting the percentage ofTopo 1Ixo-positive cells from 400 to
1000 (average 600) carcinoma cells from a morphologically well-
preserved area. The immunohistochemistry for c-erbB2, p53 and
hormone receptors was performed on adjacent tissue sections as
described previously (Kallioniemi et al, 1991a; Isola et al, 1992;
Kuukasjarvi et al, 1996). Briefly, the immunohistochemistry of c-
erbB2, p53 and hormone receptors was carried out essentially as
described above for Topo Iloc. Only intense membranous
immunostaining present in a majority of cells was taken to repre-
sent overexpression of the c-erbB2 protein. ER, PR and p53-
immunostaining in more than 20% of the tumour cells was
regarded as immunopositivity (Kallioniemi et al, 1991; Isola et al,
1992; Kuukasjarvi et al, 1996).
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Table 1 Association of clinical response to epirubicin-chemotherapy with
clinicopathological variables in 55 advanced breast cancer patients
Variable CR and PR NC PD P-valuea
All tumours 53% (29/55) 18% (10/55) 29% (16/55)
Age
< 50 years 51% (18/35) 17% (6/35) 310% (11/35)
> 50 years 55% (11/20) 20% (4/20) 25% (5/20) NS
Histological grade
or 11 43% (13/30) 27% (8/30) 30% (9/30)
IlIl 64% (16/25) 8% (2/25) 28% (7/25) NS
Oestrogen receptorb
Negative 26% (5/19) 21% (4/19) 53% (10/19)
Positive 67% (24/36) 17% (6/36) 16% (6/36) 0.0021
Progesterone receptorb
Negative 43% (12/28) 14% (4/28) 43% (12/28)
Positive 63% (17/27) 22% (6/27) 15% (4/27) 0.0409
Topoisomerase Ila
< 15% 58% (18/31) 16% (5/31) 26% (8/31)
> 15% 46% (11/24) 21% (5/24) 33% (8/24) NS
C-erbB-2 overexpression
Negative 64% (23/36) 19% (7/36) 17% (6/36)
Positive 32% (6/19) 16% (3/19) 53% (10/19) 0.0058
p53 overexpression
Negative 57% (21/37) 19% (7/37) 24% (9/37)
Mutated 44% (8/18) 17% (3/18) 39% (7/18) NS
DNA ploidy
Diploid 55% (12/22) 22% (5/22) 22% (5/22)
Aneuploid 50% (16/32) 16% (5/32) 34% (11/32) NS
S-phase fraction
< 8% 55% (11/20) 25% (5/20) 20% (4/20)
> 8% 50% (16/32) 25% (4/16) 25% (4/16) NS
Site of metastasis
Bone 50% (11/22) 9% (2/22) 41% (10/22)
Lung 0% (0/3) 100% (3/3) 0% (0/3)
Liver 50% (4/8) 0% (0/8) 50% (4/8)
All other sites 80% (4/5) 20% (1/5) 0% (0/5)
Multiple sites 63% (10/16) 25% (4/16) 22% (2/16) NS
aP-value for chi-square test for linear trend. bNegative, < 20% immunopositive
cells; positive, > 20% immunopositive cells. NS, not significant.
Our immunohistochemical determination ofTopo IIa on frozen
sections has been previously validated using Western blotting,
dual-colour immunofluorescence and mRNA in situ hybridization
(Jdrvinen et al, 1996). Now, the applicability of this assay was
extended to formalin-fixed paraffin-embedded tissue sections by
comparing Topo IIox expression from the randomly selected, sepa-
rate set of20 breast tumours from which both frozen and formalin-
fixed, paraffin-embedded tissue sections were available.
Because only primary tumours were available from epirubicin-
treated patients, we studied the correlation ofTopo IIa expression in
the primary and metastatic tumours in a separate set ofeight pairs of
primary and metastatic breast carcinomas (Kuukasjarvi et al, 1996).
Immunohistochemical controls for the ER, PR, p53 and c-erbB2
immunostainings have been established previously (Kallioniemi et
al, 1991a; Isola et al, 1992; Kuukasjarvi et al, 1996).
DNA flow cytometry
DNA flow cytometry was performed using dewaxed, rehydrated
and trypsin-treated, 50-gm-thick, paraffin-embedded sections as
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Figure 2 Correlation of the immunohistochemical determination of
topoisomerase lla protein expression between frozen and formalin-fixed,
paraffin-embedded tissue sections. A highly significant correlation was found
(r= 0.89) in 20 tumours, validating the use of paraffin sections as study
material
the starting material, using protocols described previously
(Kallioniemi, 1988). Flow cytometric analysis was carried out
using an EPICS C flow cytometer (Coulter Electronics, Hialeh,
FL, USA) and the MultiCycle software for data analysis (Phoenix
Flow Systems, San Diego, CA, USA). In DNA aneuploid
histograms, the S-phase was analysed only from the aneuploid
clone. A sliced nuclei background subtraction was performed in all
cases to compensate for the effects of nuclear debris on cell cycle
distribution (Kallioniemi et al, 1991b).
Statistical methods
Statistical analyses were carried out with an IBM-compatible
personal computer and the Biomedical Data Processing Software
(BMDP Statistical Software, Los Angeles, CA, USA). The
survival analysis was performed using the Mantel-Cox test
(program IL). The association between chemosensitivity with
prognostic factors was performed using 2 x 3 frequency tables
(using chi-square test for linear trend) (program 4F). The indepen-
dent predictive value of each marker was tested using step-wise
logistic regression analysis (program LR). The association of
chemosensitivity with Topo IIo score and S-phase fraction was
also performed using one-way analysis of variance (ANOVA with
the Welch correction for unequal variances) (program 7D).
RESULTS
Among the 55 patients treated with epirubicin, there were two CRs
(4%), 27 PRs (49%), ten patients with NC (18%) and 16 patients
with PD (29%). For all further analyses the two complete
responders were combined together with the patients with partial
response (CR and PR, n = 29). The follow-up of patients showed
that survival after administration of epirubicin was significantly
better in the favourably responding group (CR and PR) than in
patients with NC or with PD (P < 0.0016, Figure 1). Treatment
British Journal of Cancer (1998) 77(12), 2267-2273 . Cancer Research Campaign 19982270 TAH Jarvinen etal
Table 2 Step-wise logistic regression analysis of independent predictive
factors of response to epirubicin chemotherapy in 55 patients with advanced
breast cancer
Variable Relative risk of no response P-value
(95% confidence interval)
Oestrogen receptora 8.7 (1.4-53) 0.012
(negative vs positive)
C-erbB2 overexpression 5.4 (0.8-35) 0.063
(negative vs positive)
Co-variates included topo lla, p53, PR, S-phase fraction, grade, DNA ploidy.
aNegative, < 20% immunopositive cells; positive, .20% immunopositive cells.
Table 3 Association of clinical response to epirubicin chemotherapy with
topoisomerase Ila score and S-phase fraction in 55 advanced breast cancer
patients
Response to therapy
Variable CR and PR NC PD P-valuea
(n = 29) (n = 10) (n = 16)
Topoisomerase Ila 14.9 ± 11.4 15.5 + 7.6 17.3 ± 13.2 NS
S-phase fraction 11.0 + 7.2 11.6 ± 9.2 11.5 ± 6.3 NS
aANovA. NS, not significant.
before epirubicin therapy did not affect the results because epiru-
bicin was used as the first-line chemotherapy (no prior cytotoxic
drugs). Previous anti-oestrogen therapy (in 36 patients) was not
associated with response to epirubicin (P = 0.20).
The association between response to epirubicin and various
clinicopathological factors was examined as shown in Table 1.
None of the clinicopathological variables (age of patient, size of
primary tumour, axillary lymph node status, site of metastasis in
advanced disease and histological grade) was associated with
response (P > 0.05 for all variables). Among the biomarkers
studied, c-erbB2 oncoprotein overexpression (P = 0.0058), nega-
tive ER (P = 0.0021) and PR status (P = 0.041) were statistically
significantly associated with the lack ofresponse to chemotherapy
(Table 1). p53 tumour-suppressor protein accumulation, DNA
ploidy or tumour proliferation rate (S-phase fraction) were not
associated with clinical response to chemotherapy (Table 1). A
step-wise logistic regression analysis was used to demonstrate that
the predictive value of ER and c-erB2 were independent of the
Topo 11c score and other clinical and biological variables studied
(Table 2). The tumour proliferation rate (S-phase fraction) was
also analysed as a continuous variable (Table 3). Mean S-phase
fractions in responders and non-responders were similar
(11.0% ± 7.2% for CR and PR vs 11.6% ± 9.2% for NC vs
11.5% ± 6.3% for PD, not significant, Table 3).
The relationship between response to epirubicin and Topo llcc
expression was the main interest in this study and was studied in
detail. First, we validated our immunohistochemical Topo llIa
assay for formalin-fixed, paraffin-embedded sections by
comparing them with those from adjacent frozen sections used
previously (Jarvinen et al, 1996). Topo Ila scores that showed
excellent correlation were found between these two sample types
(correlation coefficient, r = 0.89, n = 20, Figure 2). Next, we
confirmed that Topo Ila expression measured in a primary tumour
sample reflects the Topo Ila status of metastasis, which is the
target of chemotherapy but from which biopsies were not avail-
able. We analysed eight pairs ofprimary tumour and asynchronous
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Figure 3 Lack of correlation between immunohistochemically determined topoisomerase Ila expression and response to epirubicin in four human breast
carcinomas. Both high and low topoisomerase Ila scores were found in tumours from the patients with favourable response (A and C, topoisomerase Ila scores
56.2% and 3.7% respectively) or from those with progressive disease despite epirubicin therapy (B and D, topoisomerase Ila scores 52.1% and 3.8%).
Haematoxylin counterstain; magnification x 240
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Figure 4 Comparison of topoisomerase Ila expression (% of
immunopositive cells) and patients' response to epirubicin chemotherapy in
55 advanced breast cancer patients. There were no statistically significant
differences in mean topoisomerase llaexpression levels between different
response groups (CR and PR, complete and partial response; NC, no change
in disease progression; PD, progressive disease). (Horizontal lines indicate
group means)
metastases (Kuukasjarvi et al, 1996) and found a good correlation
(r = 0.89), indicating stability of Topo Ioc expression during
disease progression.
To analyse Topo IIa as a predictive factor, we firstanalysed it as a
continuous variable in the differenttherapy outcome groups (Figures
3 and 4). The mean Topo IIa indexes were similar in tumours that
responded and in tumours with no clinically relevant response
(14.9% ± 11.4% for CR and PR vs 15.5% ± 7.6% for NC vs 17.3% ±
13.2% forPD, not significant, Figures 3 and4, Table 3). Figure 4 also
illustrates that it was not possible to define any threshold values for
Topo IIaexpression that could define subgroups that were associated
with response or lack of response. Because Topo IlI expression is
known to be proliferation dependent in breast cancer (Jarvinen et al,
1996), it is possible that tumour proliferation had a confounding
effect on the predictive value ofTopo IHa. By adjusting Topo IIocfor
S-phase fraction (by analysing the ratio of Topo IIo to the S-phase
fraction), this possibility was also ruled out (Topo IIa/S-phase
fraction, statistically not significant).
DISCUSSION
Numerous experimental studies have established that chemosensi-
tivity of cancer cells to Topo II inhibitors depends on the expres-
sion level of Topo 11o in the target cells (for review see
Froelich-Ammon and Osheroff, 1995; Nitiss and Beck, 1996).
Therefore, the present results showing a lack of correlation
between Topo Ixo expression and chemosensitivity clearly contra-
dict the abundant in vitro evidence (Davies et al, 1988; Fry et al,
1991; Gudkov et al, 1993; Asano et al, 1996a,b; Vassetzky et al,
1996; Withoff et al, 1996b). Our results are, however, similar to
those of two small in vivo studies on small numbers of leukaemia
and bladder cancer patients (Kaufmann et al, 1994; Davies et al,
1996). Our immunohistochemical method for the determination of
Topo Ixo has been extensively validated (Jarvinen et al, 1996) and
shown to reflect closely the exact Topo II enzyme activity of the
tissue (Yamazaki et al, 1996). We also confirmed that measuring
Topo1Ixo expression from the primary tumour (as was done in this
study) reflects the expression level in the metastasis, the actual
target of chemotherapy. In addition, we concentrated on detecting
only the ct-form of Topo II because this isoform is generally
considered to be the primary target for Topo IL-inhibiting drugs
(Froelich-Ammon and Osheroff, 1995; Nitiss and Beck, 1996),
whereas the role ofTopo IlI in relation to chemosensitivity is still
obscure (Houlbrook et al, 1996; Sandri et al, 1996; Withoff et al,
1996b). Thus, after careful validation of the analytical methods, it
is likely that Topo IIoc expression (as determined using immuno-
histochemistry) is not related with response to epirubicin in
advanced breast cancer patients. It is therefore possible that the
clinical effects of epirubicin may be mediated via other, Topo IIa
expression-independent mechanisms, such as generation of free
radicals, damage on plasma membranes, lipid peroxidation,
ceramide induction, interactions with iron and spontaneous,
position-specific DNA lesions (Epstein, 1990; Bose et al, 1995;
Kingma and Osheroff, 1997a,b).
Our study also provided important information ofthe predictive
value of other biomarkers tested. Although it is a generally held
view that the response to chemotherapy is dependent on tumour
proliferative activity, evidence supporting this concept is contro-
versial (Masters et al, 1987; Hietanen et al, 1995; Clark, 1996).
When DNA flow cytometry has been used to correlate tumour
proliferation with response to chemotherapy in advanced breast
cancer, both promising and disappointing results have been
presented (Masters et al, 1987; Hietanen et al, 1995). We did not
find a significant association between proliferation rate (S-phase
fraction) and response to epirubicin. Therefore, it is probably
premature to apply tumour proliferation assays into clinical diag-
nostics to predict the response to chemotherapy.
Another potentially predictive factor in breast cancer is the p53
tumour-suppressor protein because it has been shown that p53 is a
key trigger of apoptotic response after DNA damage caused by
cytotoxic drugs (Carson and Lois, 1995; Harris, 1996). Our results
on p53 immunohistochemical accumulation, which generally
reflects the mutation status ofthe p53 gene reliably in breast cancer
(Soong et al, 1996), did not support the role ofp53 as a significant
predictive factor in clinical breast cancer. Neither p53 alone nor p53
after its stratification by Topo IIa expression, proliferation rate or
any other factor showed predictive value for chemotherapy
response. Thus, the relationship between apoptosis regulators and
response to chemotherapy is likely to be more complex. Othergenes
such as the tumour-suppressor gene p21WAF/CIPi, which recognizes
Topo II inhibitor-induced DNA damage (Gartenhaus et al, 1996;
Jacks and Weinberg, 1996), may be also involved in this process.
Among the other biomarkers tested, we identified a strong
correlation between hormone receptor status and response to
epirubicin. This relationship was especially strong for oestrogen
receptor; positive ER expression predicting good response to
therapy. The relationship between Topo II inhibitor chemotherapy
and hormone receptor content has also been reported previously in
two larger studies (Falkson et al, 1991; Muss et al, 1994).
Together, these studies indicate that favourable response to
cytotoxic drugs is common in primarily ER-positive tumours,
although many of these patients had initially responded and then
become resistant to preceding hormonal therapy. The explanation
for this phenomenon is unknown. Preliminary in vitro evidence
suggests that the absence of oestrogen-mediated signalling path-
ways (ER negativity) is associated with impaired ability ofthe cell
cycle checkpoints to detect the DNA damage by cytotoxic drugs
(Guillot et al, 1996; 1997).
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In addition to the predictive value of hormone receptors, the
significant association ofc-erbB2 overexpression and resistance to
epirubicin is also of particular interest. Previous chemotherapy
regimens containing topo II inhibitors have linked c-erbB2 either to
sensitivity (Muss et al, 1994) or to resistance (Wright et al, 1992;
Ravdin and Chamness, 1995; Bitran et al, 1996), whereas in vitro
studies relate c-erbB2 amplification exclusively to chemoresistance
(Pietras et al, 1994; Tsai et al, 1996; Zhang et al, 1996). The biolog-
ical mechanism underlying this association is so far unknown.
Simultaneous aberrant expression of Topo Ila and c-erbB2 has
been suggested as an explanation (Muss et al, 1994; Jarvinen et al,
1996; Murphy et al, 1996) because both genes are located adjacent
to each other at chromosome 17q12. To support this theory, simul-
taneous amplification of these two genes has been reported in
breast cancer cell lines and in clinical breast cancer samples (Keith
et al, 1993; Smith et al, 1993; Matsumura et al, 1994; Murphy et al,
1996). In addition, the Topo Iloa gene may even be physically
deleted in conjunction with c-erbB2 amplification (Matsumura et
al, 1994). Furthermore, high-level Topo Ila expression was associ-
ated with c-erB2 overexpression in a large series ofbreast tumours
(Jarvinen et al, 1996). However, our step-wise logistic regression
analysis clearly showed that the adjustment of variability of Topo
IIxc expression had no effect on the predictive value of c-erbB2.
Therefore, other mechanisms explaining the association ofc-erbB2
amplification and poor response are probably more relevant.
Although c-erbB2 itself is not a molecular target for cytotoxic
drugs, increased tyrosine kinase activity caused by c-erbB2 ampli-
fication may be associated with chemoresistance (Pietras et al,
1994; Tsai et al, 1996; Zhang et al, 1996). Increased tyrosine kinase
activity may directly increase repair of DNA damage caused by
cytotoxic drugs (Pietras et al, 1994), thereby making the cells able
to avoid apoptosis despite drug treatment.
In conclusion, the present study shows that the response to the
Topo II-inhibiting cytotoxic drug, epirubicin, could not be
predicted by Topo 11c expression in advanced breast cancer. The
response was significantly associated with c-erbB2 overexpression
and ER status, indicating that these widely used prognostic factors
may have additional value as the predictors of response to first-
line anthracycline chemotherapy.
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